REVIEW

Schiff Base Metal Complexes as Anticancer Agents

G. SRIDEVI^{1,2,*}, S. ARUL ANTONY³ and R. ANGAYARKANI¹

¹Department of Chemistry, Sriram Engineering College, Chennai-602024, India

²R&D Centre, Bharathiar University, Coimbatore-641046, India

³PG and Research Department of Chemistry, Presidency College, Chennai-600005, India

*Corresponding author: E-mail: sridevi.lec@gmail.com

Received: 5 September 2018;

Accepted: 15 October 2018;

Published online: 31 January 2019;

AJC-19234

Cutting-edge practices in bioinorganic chemistry are pivotal for enhancing the layout of compounds to lessen poisonous facet effect and recognize their mechanism of action. A powerful anticancer agent should own inherent, inhibitory property and also delivery, dosage and residence time *in vivo*. Organic function and conformation of mutated gene may be altered by way of binding of metal ions. Upswing of activities counting on the structural data, intending in enhancing and growing different forms of metal based compounds, continuous seek of extra metal based compounds have been synthesized *via* revamping the prevailing chemical shape *via* ligand substitution. The prevailing paper addresses the trendy development in the design of novel antitumor agents primarily based on transition metal complex *via* highlighting the near dating among their structural alternatives and cytotoxic ability.

Keywords: Schiff base, Mutated gene, Antitumor agents, Cytotoxic ability.

INTRODUCTION

Cancer is brought on when genetic harm to the cells prevents them from being attentive to regular tissue controls. The most cancers spreads when affected cells multiply rapidly, forming tumors of varying tiers. Special healing procedures can be used, depending on how a long way the most cancers have spread [1-4]. Within the case of most cancers, a chemotherapeutic agent is one which kills the swiftly dividing cells, accordingly slowing and stopping the cancer from spreading. The two principal sample of cancer cellular invasion, collective cellular migration and individual cellular migration with the aid of which tumor cells conquer limitations of extracellular matrix and spread into surrounding tissues. Two styles of migrating tumor cells, mesenchymal (fibroblast-like) and amoeboid are discovered in each pattern of cancer cell invasion [5]. Anticancer drugs have been grouped as chemotherapy, hormonal remedy and immunotherapy. Chemotherapy protected a number a families defined by way of each their chemical structure and mechanism of action, alkylating agents, antibiotics, antimetabolites, mitosis inhibitors and so on [6].

Metal complexes play a crucial role in drug remedy. the metallo-elements present in shred quantity performs vital function in residing device on the molecular stage [7]. Transition metals exhibits various oxidation states and might engage with a number of negatively charged molecules. This property of transition metal has unraveling the metal based drugs with promising pharmacological pertinence [8]. The invention of cisplatin, *cis*-[Pt^{II}(NH₃)₂Cl₂], become a defining moment which induced the interest in platinum(II) and other metal containing complexes as ability novel anticancer drugs [9]. Emerging metal complex as drugs, however, isn't a smooth project. Deposition of metal ions inside the body can cause deleterious effects. As a consequence biodistribution and clearance of the metal complexes as well as its pharmacological specificity are to be taken into consideration. Reverent physiological responses of candidate drugs want to be validated with the aid of *in vitro* study with focused biomolecules and tissues in addition to *in vivo* investigation earlier than they input medical trials. A conceptual knowledge of how metallic complexes attain their activities is essential to their clinical achievement, in addition to the rational design of latest compounds with improved potency. Metal

impact influences no longer best herbal tactics, which include cell division and gene expression, but also non-natural processes, inclusive of toxicity, carcinogenicity and antitumor chemistry. In chemotherapy, the important issue is killing the tumor cells, without causing too much damage to healthy cells [2-4]. Metal complexes formed with other metals like copper, gold, gallium, germanium, tin, ruthenium and iridium showed significant antitumor activity. In this review, we highlighted the current progress based on the interface between molecular biology and bioinorganic chemistry the design of coordination complexes for cancer treatment.

Cause of cancer: The reasons of most cancers are numerous, complex and handiest in part understood. Many elements together with environmental (vitamins/weight loss program, tobacco use, sure infections, publicity to radiation, lack of bodily activity, obesity and pollution) and inner/genetic components (inner factors inclusive of inherited mutations/differences, hormones, and immune situations), play an important position to boom the threat of most cancers. The contribution of genetic elements and environmental factors closer to most cancers hazard is round 5-10 % and 90-95 %, respectively. At some stage in metabolic process in human body oxygen-centered free radicals and different sensitive oxygen species may additionally yield as by-product by way of numerous physiological and biochemical adjustments. Overproduction of such free radicals can reason of oxidative harm to biomolecules (*e.g.* proteins, lipids, DNA), in the long run leading to several chronic diseases, consisting of atherosclerosis, cancer, diabetes, growing older and other degenerative sicknesses in humans.

Mechanism of anticancer drugs: The central dogma of molecular biology is deoxyribose nucleic acid (DNA) to ribonucleic acid (RNA) to protein synthesis. DNA, a genetic material of cell acts as the selective template for the production of precise varieties of transfer, ribosomal and messenger ribonucleic acid (RNA). DNA, in directing the formation of particular sequences of messenger RNA, determines which proteins can be synthesized at the RNA templates. The enzymes in flip are responsible for the shape, metabolic interest, proliferative charge and function of the cellular. Interference with the shape of DNA (alkylating agents, procarbazine) or its feature disorganizes and disrupts the cell. Compounds with this mechanism of movement had been useful anticancer drugs.

A new lanthanide Schiff base ligand, N^2, N^3 -bis (anthracen-9-ylmethylene)pyridine-2,3-diamine (SBL) (Fig. 1) is synthesized *via* condensation of 2,6-diaminopyridine and anthracene-9-carbaldehyde using a 1:2 ratio. ^1H NMR spectra confirmed the non-involvement aromatic carboxylic proton in SBL. A unique series of lanthanide (*i.e.*, praseodymium, erbium and ytterbium)-based totally SBL steel complexes become efficiently synthesized and their usefulness had been elaborately established using UV-visible, FT-IR and fluorescence spectroscopy analyses. The synthesized SBL-based metal complexes were elaborately carried out for cytotoxicity activity as opposed to vero, human breast cancer (MCF7), and cervical (hela) anti-cancer cell traces. SBLPR and SBLER effectively brought on apoptosis in vero MCF7 and Hela cells in a dosage based manner. the SBLPR tested vero cells displayed a terrific biocompatibility in comparison to the complicated SBLER. The morphological

Fig. 1. Structure of lanthanide Schiff base complex

shots showed the poisonous effect of SBLPR and SBLER pattern in opposition to vero cells compared with control cells [10].

Schiff base ligands prepared from *o*-vanillin, (*R*)-(+)-2-amino-3-phenyl-1-propanol and 2-amino-2-ethyl-1,3-propanediol. These ligands were treated with Zn metal to form Zn complexes (Fig. 2) and characterized. The *in vitro* cytotoxicity of metal complexes towards four kinds of cancerous cell lines (A549, HeLa, HL-60 and K562) were assayed by MTT method. Investigations on the chirality and nuclearity of zinc complexes showed that they play an important role in cytotoxic activity [11].

Sheikh *et al.* [12] synthesized new type of tetradentate nitrogen donor (N4) Schiff base ligand (Fig. 3). The ligands prepared were reacted with Cu(II), Ni(II) and Co(II). All the metal compounds synthesized were tested for cytotoxic activity by MTT assay on H9C2 cardiac myoblast. The results showed that Ni(II) complex was very active and less cytotoxic among all the metal chelates screened [12].

New Schiff base ligand with molecular formula ($\text{C}_{20}\text{H}_{23}\text{NO}_3$), has been prepared and treated with copper metal [13]. The copper metal complex was screened for spectroscopic analyses. The *in vitro* cytotoxicity of copper metal complex were tested by MTT assay on different cancer cell line. Investigated results showed that copper complex (Fig. 4) show positive synergic effect and high selective in dose dependent manner [13].

Another new copper(II) complex (Fig. 5) was synthesized and its antiproliferative effect on HT-29 colon cancer cells were investigated [14]. The copper complex has a potent antiproliferative effect with IC_{50} value of $2.87 \mu\text{g/mL}$. Moreover, the copper complex when treated with HT-29 cells underwent apoptosis death and showed a elevation in cell population and also at a concentration of $6.25 \mu\text{g/mL}$, the complex shows more elevation. All these results implied that the copper(II) complex possesses potential ability for future *in vivo* and as cancer cell line to develop chemotherapeutic agents [14].

Pyridine based cobalt metal complex were synthesized and characterized by Xiao *et al.* [15]. The pyridine-metal complex (Fig. 6) were screened for *in vitro* cytotoxic studies in which three human skin cancer cell lines (A-431, HT-144 and SK-MEL-30) were used. The antiproliferative effect of test compounds in opposition to each of tumor cell lines can

Fig. 2. Zn complex from *o*-vanillin and (*R*)-(+)-2-amino-3-phenyl-1-propanol

Fig. 3. Structure of macrocyclic tetradentate nickel complex

Fig. 5. Structure of $\text{Cu}(\text{BrHAP})_2$ Schiff base

Fig. 4. Structure of copper complex with imine moiety

Fig. 6. Structure of metal complexes of Py_3CoL_1 (a) and Py_3CoL_2 (b)

be arranged in a lowering order in keeping with the measured concentration required to inhibit tumor cell proliferation by 50 % ($\text{IC}_{50} \mu\text{M}$). The results confirmed that the compounds exhibited widespread growth inhibition interest at three tumor

cell lines in comparison to their corresponding organic ligand [15].

Co(II), Ni(II), Cu(II) and Zn(II) complexes (Fig. 7) derived from vanillin and acetoacetanilide with ethylenediamine were synthesized as reported by Kumar and Varma [16]. The ligand and its metal complexes were tested for cytotoxic activities and found that copper complexes have higher inhibitory concentration (IC_{50}) value around 49 $\mu\text{g/mL}$. DLA cell induced solid tumor model and EAC cell induced ascites tumor model were mainly used for antitumor studies. Copper complexes were administered at different concentrations in Swiss albino mice to access increases in the survival rate and the life span of ascites tumor enduring mice in a dose dependent manner [16].

Fig. 7. Structure of metal complexes derived from vanillin and ethylenediamine

Tin(IV) complexes (Fig. 8) have been synthesized from $N'-[(1E)-(2\text{-hydroxy-3-methoxyphenyl})\text{methylidene}]pyridine-4\text{-carbohydrazone}$ [17]. The five human tumor cell lines (HL-60, A549, HT-29, HCT-116 and Caco-2) were screened for *in vitro* cytotoxicity by MTT assay. These complexes show better antiproliferative outcomes in cultured cancerous cells and their cytotoxic activity correlates with intracellular organotin(IV) concentration. Studies revealed that the diphenyl tin compounds have less cytotoxicity interaction than tin(IV) complex [17].

The novel synthesis of disubstituted hexahydroquinolines substituted with benzensulfonyl and phenylthiocarbamoyl pharmacophores (Fig. 9) that are known to contribute to chemotherapeutic effects is described [18]. The six synthesized compounds were able to show remarkable cytotoxic efficiency against human

Fig. 9. Structure of quinoline based Schiff base ligand

colon carcinoma HT29, breast adenocarcinoma MCF7 cell lines and hepatocellular carcinoma Hep-G2. Overall, the study of the results revealed that compounds could be considered as effective in both antimicrobial-anticancer agents [18].

A major challenge in cancer drug discovery was selective cytotoxic effect towards tumour cells but not the normal cells. The HTT (Fig. 10) compounds were synthesized and their antitumour activity was evaluated. The derived compounds were investigated against K562 leukemia cells and MCF-7 normal cells. The compounds showed significant antitumour activity against Leukemia K562 cells. With reference to cytotoxicity in normal cells, compounds showed no cytotoxic effect within 200 μm but compounds showed non-selective cytotoxic effect [19].

Fig. 10. Structure of HHT Ligand

Fig. 8. Structure of tin complexes from pyridine

The Cu(II), Mn(II), Ni(II), Zn(II) and Ag(I) metal complexes with oxaloamide ligand are effective in therapeutics as well as diagnostic agents. Specific examples involving the design of metal complexes (Fig. 11) as antitumor agents are discussed. The screening of cytotoxicity of metal complex with IC_{50} value has been carried out. Copper(II) complexes show increased activity in comparison to the parent ligand or standard drug. Copper is used in various human cancer cell line and it is a co factor which is essential for tumour angiogenesis process. The targeted tumour cell are treated with copper binding ligand, where copper can acts as a better selective cancer drugs [20].

Fig. 11. Structure of metal complexes of oxaloamide ligand

Transition metals like Cr(III), Ni(II), Cu(II), Ru(III), Mn(II) and Zn(II) ions were prepared from heterocyclic furan based Schiff compounds (Fig. 12). The metal complexes were evaluated against human breast (MCF-7) and lung cancer (A549) cell lines. The cytotoxic activities of all compounds were better towards human breast (MCF-7) and lung cancer (A549) cell lines [21].

Fig. 12. Structure of metal complexes derived from Schiff base containing heterocyclic furan moiety

Schiff bases derived from 4-aminoantipyrene (Fig. 13) were investigated for the effect of nitro group on its antibacterial activity, antitumor study of effects of electron withdrawing and donating group on antioxidant potential. The compounds were synthesized with less time using green method. These compounds show significant cytotoxic activity results due to the presence of NO_2 group [22].

Fig. 13. Structure of 4-amino antipyrene derived ligand

Cu(II), Ni(II) and Zn(II) complexes with Schiff base, 2-((E)-(5-methylisoxazol-3-ylimino)methyl)-4-methoxyphenol (MIIMMP) (Fig. 14) were prepared in an ethanolic medium [23]. Based on spectral data and molecular modeling data, Ni(II) and Zn(II) metal complexes have octahedral geometry, whereas Cu(II) complex has tetragonal geometry. The antimicrobial activity and cytotoxic activities of ligand and its metal complexes were studied on bacteria, fungi and human cervical carcinoma cells (HeLa). Metal complexes provide good results against cytotoxicity.

Fig. 14. Structure of 2-((E)-(5-methylisoxazol-3-ylimino)methyl)-4-methoxyphenol (MIIMMP)

Schiff base transition metal complexes (Fig. 15) were synthesized by the condensation of isonicotinohydrazide with 1-phenyl indoline-2,3-dione [24]. The DNA cleavage and *in vitro* cytotoxicity of metal complex were performed by agarose gel electrophoresis method and MTT assay. The results showed that Ni(II) and Cu(II) complexes show better cytotoxic activity on AGS-human gastric cell line than ligand [24].

Fig. 15. Schiff base transition metal complexes derived from isonicotinohydrazide and 1-phenyl indoline-2,3-dione

Several heterocyclic Schiff base copper complexes were designed and characterized (Fig. 16). The ligands and the metal complexes were tested against antibacterial and antifungal species by paper disc method. The ligand and metal complexes were also screened for antitumour activity against the human cervical carcinoma cancer cell line (Hela). The studies showed that few copper complexes exhibit good antitumour activity on Hela cell line [25].

Platinum(II) Schiff base ligand that derived from 5-chloro-salicylaldehyde and *o*-phenylenediamine was synthesized and characterized (Fig. 17) [26]. The *in vitro* cytotoxicities of metal chelates had been investigated through microculture tetrazolium (MTT) assay against seven human tumor cell lines. Cell cycle evaluation indicated that the complex prompted apoptosis and G1-phase arrest in A549 cells. The outcome confirmed that the complex could suppress the proliferation and viability of a549 cells by colony formation assay [26].

Palladium(II) *bis*-chelates compounds had been synthesized and characterized through elemental analysis and spectroscopic techniques (Fig. 18) [27]. The structure of ligand and metal complex has been determined by single crystal X-ray diffraction studies. The *in vitro* cytotoxic action of complexes indicate that the palladium(II) complexes exhibited better antiproliferative interest than their free ligands towards different types of human cancer cell lines. Among all the studied palladium complexes, the newly synthesized palladium complex exhibited more antitumor activity on the DU145 prostate carcinoma and K562 chronic myelogenous leukemia cells, with low values of the inhibitory concentration [27].

Various heterocyclic nuclei (pyridine, *N*-methyl-pyrrole or imidazole) at C-2 are introduced in heterocyclic benzimidazole derivatives bearing amidino substituents at C-5 of benzimidazole ring (Fig. 19) and evaluated for their antitumor and antiviral activities. The substituent having imidazolinyamidino

Fig. 16. Structure of copper complexes of DMIIMBP

Fig. 17. Synthesis of platinum Schiff base complex

Fig. 18. Synthesis of palladium Schiff base complex

Fig. 19. Structure of benzimidazole Schiff base

produced most pronounced antiproliferative activity. Stimulately, all compounds show distinguishable selectivity toward breast cancer cell line MCF-7 [28].

Novel 2-oxoquinoline-3-carbaldehyde Schiff base ligands and their Cu(II) complexes were synthesized and analyzed (Fig. 20) [29]. The prepared ligands and their Cu(II) complexes were explored for their potential anticancer activity by MTT assays indicated that Cu(II) complexes exhibited more effective cytotoxic activity against HL60 cells, HeLa cells and potential DNA binding efficiency compared to the corresponding ligands. Complexes show more cytotoxic activity than the ligand [29].

Using an absorption titration technique, copper Schiff base complex (Fig. 21) with a distorted tetrahedral geometry has been discovered to reveal interplay through intercalation with CT-DNA [30]. The cytotoxic impact of complex analyzed on carcinocell lines (human cervical cancer cell line (HeLa), human laryngeal epithelial carcinoma cell line (Hep-2) and human breast cancer cell line (MCF-7)) demonstrated that the complex displayed extensive anticancer activity. The IC_{50} values of Cu complex were 3.04, 19.25 and 4.34 μ M, for HeLa, Hep-2 and MCF-7 cancer cell lines. In comparison to cisplatin, the Cu(II) complex displayed three times higher inhibitory activity against HeLa and MCF-7 [30].

Fig. 21. Structure of heterocyclic copper Schiff base

By the condensation of salicylaldehyde with 2-amino-4-phenyl-5-methyl thiazole, a ligand was prepared and forms complexes with Co(II), Ni(II), Cu(II) and Zn(II) (Fig. 22) [31]. The human tumor cell lines: breast cancer MCF-7, liver cancer HepG2, lung carcinoma A549 and colorectal cancer HCT116

Fig. 20. Structure of copper complexes of 2-oxoquinoline-3-carbaldehyde Schiff base

were tested with the synthesized compounds for their anti-cancer activity with the activity of doxorubicin as a reference drug. Evaluation on result showed that the Zn(II) complex showed potent inhibition against human TRK in the four cell lines in the ratio 80, 70, 61 and 64 % for (HepG2, MCF7, A549, HCT116) when compared to the inhibition in the untreated cells [31].

Shafeeulla *et al.* [32] tested the human breast cancer MCF-7, cervical cancer cell HeLa K-562 and Vero cell lines at the concentrations of 80, 90, 100, 120, 130 and > 200 mg/mL for 48 h using pyridine Schiff base ligand and its metal complexes (Fig. 23). The cell growth inhibition was analyzed by the MTT assay and the results revealed that complexes and the ligand exhibited an inhibitory effect on the proliferation of HeLa, MCF-7 and Vero cell lines in a dose-dependent manner [32].

Isooxazole Schiff base with 1,10-phenanthraline were condensed and react with nickel to form metal complex (Fig. 24) [33]. The antitumor activities of the metal complex with human promyelocytic leukemia (HL60) tumor cell were investigated by MTT assay. The cytotoxic activity of the complex shows good results against human promyelocytic leukemia (HL60) [33].

Schiff base metal complexes containing thiazole based coumarin compounds were synthesized and reported by Sahin *et al.* [34] (Fig. 25). The antitumor activity of ligand and its Pt and Pd metal complexes are tested using MTT assay. The various cancerous cell line such as MCF-7 (human cancer cell line), LS174T (human colon carcinoma cell line), LLCAP (human prostate adeno carcinoma) were tested with ligand and metal complexes. The antiproliferative activities of metal complexes were high which was determined by IC_{50} value. The results showed that Pd(II) complex as higher antitumor effects [34].

Organometallic platinum complexes containing a chloride, *cis*-cyclooctene and a Schiff base ligand have been prepared and characterized (Fig. 26) [35]. Three aliphatic amines and four aromatic amines were chosen as representative examples. The imine functionality is *trans* to organic cyclooctene group. Complex which contained the longest aliphatic chain studied (octyl group), was the most promising for inducing apoptosis in the malignant MB231 breast cancer cell line. Conversely, complexes which contained aromatic groups, were the most active against renal cell carcinoma (RCC) cell lines [35].

Manikandan *et al.* [36] have reported the Co(II) complexes of 2-acetylpyridine N-substituted thiosemicarbazone with $(PPh_3)_2$ (Fig. 27). The higher cytotoxic activity for the complex substituted benzene may be due to the terminal phenyl substitution of coordinated ligand. By comparing the cytotoxicity with conventional standard cisplatin, it is found that the complexes exhibited excellent activity in both cancer cell lines. However,

Fig. 22. Synthesis of Schiff base metal complexes containing thiazole moiety

Fig. 23. Synthesis of pyridine Schiff base metal complex

the cytotoxic activity of complexes against human breast cancer cell line (MCF-7) stood higher than that of skin carcinoma cell line (A431).

Fig. 24. Structure of nickel(II) complex of isooxazole Schiff base with 1,10-phenanthroline Schiff base

Fig. 25. Synthesis of coumarin thiazole Schiff base metal complexes

Fig. 26. Synthesis of platinum cyclooctene complexes

Fig. 27. Structure of 2-acetylpyridine N-substituted thiosemicarbazone Schiff base cobalt(II) complex

Zinc, silver and palladium complexes of 6-amino-4-hydroxy-2-thiopyrimidine have been synthesized and characterized (Fig. 28) [37]. The free Hahtp and its complexes, $[\text{Zn}(\text{ahtp})_2(\text{H}_2\text{O})_2]$, $[\text{Zn}(\text{Hahtp})_2(\text{PPh}_3)(\text{H}_2\text{O})]$, $[\text{Zn}(\text{Hahtp})(\text{bpy})\text{Cl}_2]$, $[\text{Pd}(\text{phen})(\text{Hahtp})\text{Cl}]$ and $[\text{Ag}(\text{Hahtp})(\text{PPh}_3)(\text{H}_2\text{O})]$ have been tested

Fig. 28. Structure of Hahtp Schiff base complexes of Pd, Ag and Zn

Fig. 29. Structure of Hdahmp Schiff base metal complexes

against the human breast cancer MDA-MB231 cell line. The $[\text{Ag}(\text{Hahtp})(\text{PPh}_3)(\text{H}_2\text{O})]$ complex exhibits the highest efficacy with a mean IC_{50} value of $4.7 \mu\text{M}$.

Similarly, few metal complexes were synthesized using the ligand 5,6-diamino-4-hydroxy-2-mercaptopyrimidine (Fig. 29) [38]. There are different types of mode of chelation involved in these metal complexes. These metal complexes were also evaluated against the human serous ovarian cancer cell line (OV-90) and human ovarian cancer cell line (OVCAR-8). The metal complexes exhibit high potential cytotoxic activity [38].

El-Deen *et al.* [39] reported few metal (Zn, Pt, Pd) complexes when reacted with piperidine-2-carboxylic acid. The free piperidine ligand and their metal complex are tested for their *in vitro* cytotoxicity on serous ovarian cancer, OV 90 cell line. The metal complexes exhibit good cytotoxic activity [39].

Ruthenium compounds include ruthenium cluster, ruthenium platinum mixed compound, ruthenium DNA intercalators have the ability to form supramolecular architecture and multi-nuclear complex. It is very less toxic metal and has the ability to mimic iron binding serum protein which reduces the concentration of free plasma ruthenium and increases the concentration that affect the cancer cells when compared to the healthy cells. Ruthenium complexes with plasma bounding possess high affinity to tumour cells with transferring receptors [40].

Shen *et al.* [41] reported the synthesis and characterization of divalent transition metal complexes *e.g.*, Co(II), Cu(II), Cd(II) and Mn(II) with nicotinothiazide ligand. The complex also used for *in vitro* cell experiment to test the antitumour effect. The results revealed that the uncomplexed ligand show cytotoxic effect than the metal complexes. Metal complexes can effectively decrease the proliferation rate of different type of cancerous cell line like human gastric cancer cells, human esophageal cancer cell line (ECA109) in a dose dependent manner [41].

Schiff base copper(II) complexes containing mixed ligands salicylic acid and benzoic acid were synthesized as reported by Lian *et al.* [42]. The complexes were evaluated against the cytotoxicity of cancer cell line (human cervical carcinoma Hela) and human liver hepatocellular cancer cell line HepG-2). The colorimetric cell proliferation assay and clorogenic assay showed that these complex have improved cytotoxicity. Copper complex containing salicylic acid as a auxiliary ligand displayed a stronger anticancer activity [42].

Benzimidazole Schiff base ligand have been synthesized by the condensation of 2-hydroxy-1-naphthaldehyde and 2-((1-*R*-1-*H*-benzimidazol-2-yl)phenyl-imino)naphthol. The ligands were treated with $\text{Cu}(\text{NO}_3)_2$ to give copper(II) metal complexes. The complexes showed *in vitro* cytotoxic effect against human

lung cancer cell line (A549) breast cancer cell line (MDA-MB-231) and cervical cancer cell line (Hela). The metal complexes exhibit significant effect on the proliferation of A-549 cancer cell line [43].

Benzimidazole moiety containing Schiff base ligands were prepared and formed copper complexes. These metal complexes were evaluated against various human breast cancer cell line (MCF-7) cell line and human colorectal cancer cell line (COLO205). The cytotoxic and antiproliferative activity of metal complexes against MCF-7 line show IC_{50} value = $16.9 \pm 1.5 \mu\text{mol}^{-1}$ and for colorectal cancer cell line the IC_{50} value = $16.5 \pm 3.4 \mu\text{mol}^{-1}$ which is stronger than the ligand and can have the potential to act as anticancer drug [44].

Gaber *et al.* [45] synthesized Schiff base ligand and its Ni(II), Pt(II) and Pd(II) complexes by the condensation of 2-hydroxy-1-naphthaldehyde and 3-amino-1,2,4-triazole. The antitumour activity of metal complexes were investigated for liver carcinoma (HepG-2) cell line. The results showed that ligand has greater cytotoxic activity than metal complexes.

Chiral Schiff base metal complexes of copper and nickel were synthesized from R/S-2-[1-hydroxymethylpropylimino)-methyl]-5-methoxyphenol and its derivatives. The *in vitro* cytotoxicity activity of the complexes were investigated for various human lung cervical cell line (Hela), human lung adenocarcinoma (A549) and human breast cancer cell line (MCF-7) by the MTT assay. The results showed that copper and nickel complexes exhibited good cytotoxic activity [46].

Diacetone based copper(II) complexes were synthesized using 1-naphthyl N,N [bis(2-pyridyl)methyl]amines. The cancerous cell line such as (Hela, MCF-7, Bel-7404 and HepG-2) were tested for *in vitro* cytotoxicity of the metal complexes. All the metal complexes exhibit high potential cytotoxic effect with less IC_{50} value. The studies showed that the antitumour activity of metal complexes were stronger [47].

Jiao *et al.* [48] also reported a new dinuclear copper(II) complex by condensing 2,2'-diamino-4,4'-bithiazole with N-[3-dimethylamino)propyl]-N'-(2-carboxylatophenyl)oxamide. The copper(II) complexes were tested for *in vitro* anticancer activities. The copper complexes were more active against the cancerous cell line and act as a better dose dependent cytotoxic drug.

Nickel salicylidene Schiff base metal complex were synthesized and characterized by Li *et al.* [49]. The coordination of nickel(II) ion by ONNO donor in a tetradentate manner have been confirmed by single crystal X-ray structure. The complex were examined for the *in vitro* cytotoxicity on cancerous cell lines such as human coloncarcinoma cell line (HCT-116), human lung carcinoma line (A549) and colonic cancer cell line (CaCo-2). The results showed that all the nickel complexes exhibit high potential cytotoxic activity.

Jaividhya *et al.* [50] synthesized a series of mixed ligand copper(II) complexes of anthracene based Schiff base ligand with 1,10-phenanthroline. The *in vitro* cytotoxicity of the ligand were tested against human breast cancer cell line MCF-7. The studies show that the IC_{50} value is less than that of cisplatin for the same cell line and can act as better cytotoxic drug.

Rajarajeswari *et al.* [51] synthesized a new series of Cu(II) complex of tridentate ligand with two nitrogen donor like 2-(2-

(1*H*-benzimidazole-2-yl)ethylimino methyl)phenol with 1,10-phenanthroline and also chloride complex of tridentate ligands. The copper complexes were investigated with human breast cancer cell line (HBL-100) by MTT assay. It was found that copper(II) complex with two nitrogen donor atom exhibited more potential to act as efficient cytotoxic drug than the chloride complex [51].

Conclusion

Latest advances in bioinorganic chemistry gives considerable possibilities for the utilization of metal complexes inside the improvement of anticancer capsules. The researchers attempted to discover the complicated, mechanism of action and showed that rather than inducing apoptosis the compound arrest cellular cycle development. The destiny development of medicinal inorganic chemistry requires an understanding of the physiological processing of metal complexes to offer a rational basis for the layout of recent metal based tablets.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interests regarding the publication of this article.

REFERENCES

1. H. Ali and J.E. van Lier, *Chem. Rev.*, **99**, 2379 (1999); <https://doi.org/10.1021/cr980439y>.
2. A.Y. Louie and T.J. Meade, *Chem. Rev.*, **99**, 2711 (1999); <https://doi.org/10.1021/cr9804285>.
3. W.A. Volkert and T.J. Hoffman, *Chem. Rev.*, **99**, 2269 (1999); <https://doi.org/10.1021/cr9804386>.
4. H. Grunicke, W. Doppler and W. Helliger, *Arch. Geschwulstforsch.*, **56**, 193 (1986).
5. N.V. Krakhmal, M.V. Zavyalova, E.V. Denisov, S.V. Vtorushin and V.M. Perelmutter, *Acta Naturae.*, **7**, 17 (2015).
6. E. Espinosa, P. Zamora, J. Feliu and M. González Barón, *Cancer Treat. Rev.*, **29**, 515 (2003); [https://doi.org/10.1016/S0305-7372\(03\)00116-6](https://doi.org/10.1016/S0305-7372(03)00116-6).
7. K. Hariprasath, B. Deepthi, I. Sudheer Babu, P. Venkatesh, S. Sharfudeen and V. Soumya, *J. Chem. Pharm. Res.*, **2**, 496 (2010).
8. S. Raffique, M. Idrees, A. Nasim, H. Akbar and A. Athar, *Biotechnol. Mol. Biol. Rev.*, **5**, 38 (2010).
9. M. Frezza, S. Hinde, D. Chen, A. Davenport, S. Schmitt, D. Tomco and Q. Ping Dou, *Curr. Pharm. Des.*, **16**, 1813 (2010); <https://doi.org/10.2174/138161210791209009>.
10. K. Andiappan, A. Sanmugam, E. Deivanayagam, K. Karuppasamy, H.-S. Kim and D. Vikraman, *Sci. Rep.*, **8**, 3054 (2018); <https://doi.org/10.1038/s41598-018-21366-1>.
11. M.-J. Niu, Z. Li, G.-L. Chang, X.-J. Kong, M. Hong and Q.-F. Zhang, *PLoS One*, **10**, e0130922 (2015); <https://doi.org/10.1371/journal.pone.0130922>.
12. R.A. Sheikh, M.Y. Wani, S. Shreaz and A.A. Hashmi, *Arab. J. Chem.*, **9**, 743 (2016); <https://doi.org/10.1016/j.arabj.2011.08.003>.
13. Z. Shokohi-pour, H. Chiniforoshan, A.A. Momtazi-borojeni and B. Notash, *J. Photochem. Photobiol.*, **162**, 34 (2016); <https://doi.org/10.1016/j.jphotobiol.2016.06.022>.
14. M. Hajrezaie, M.J. Paydar, S.Z. Moghadamtousi, P. Hassandarvish, N.S. Gwaram, M. Zahedifard, E. Rouhollahi, H. Karimian, C.Y. Looi, H.M. Ali, N.A. Majid and M.A. Abdulla, *Sci. World J.*, **2014**, 540463 (2014); <https://doi.org/10.1155/2014/540463>.
15. Y.J. Xiao, Q.C. Diao, Y.H. Liang and K. Zeng, *Braz. J. Med. Biol. Res.*, **50**, e6390 (2017); <https://doi.org/10.1590/1414-431X20176390>.
16. K.S. Kumar and C. Priya Varma, *J. Pharm. Sci. Res.*, **9**, 1317 (2017).
17. M. Hong, H. Geng, M. Niu, F. Wang, D. Li, J. Liu and H. Yin, *Eur. J. Med. Chem.*, **86**, 550 (2014); <https://doi.org/10.1016/j.ejmech.2014.08.070>.

18. H.M. Faidallah, A.A. Saqer, K.A. Alamry, K.A. Khan, M.A.M. Zayed and S.A. Khan, *Asian J. Chem.*, **26**, 8139 (2014); <https://doi.org/10.14233/ajchem.2014.17616>.
19. A.A. Radwan, T. Aboul-Fadl, A. Al-Dhfyhan and W.M. Abdel-Mageeda, *Asian J. Chem.*, **26**, 8145 (2014); <https://doi.org/10.14233/ajchem.2014.17636>.
20. A.S. El-Tabl and M.S. Ahmed Shahin, *Int. J. Adv. Chem.*, **4**, 01 (2018). <https://doi.org/10.5121/ijac.2018.4101>.
21. A.S. Alturqi, A.-N.M. A. Alaghaz, R.A. Ammar and M.E. Zayed, *J. Chem.*, **2018**, 5816906 (2018); <https://doi.org/10.1155/2018/5816906>.
22. M.M. Shoaib, G. Rahman, S.W. Ali Shah and M.N. Umar, *Bangladesh J. Pharmacol.*, **10**, 332 (2015); <https://doi.org/10.3329/bjpv.v10i2.22471>.
23. K. Sathish Kumar, V.K. Chityala, N.J.P. Subhashini, Y. Prashanthi and Shivaraj, *ISRN Inorg. Chem.*, **2013**, 562082 (2013); <https://doi.org/10.1155/2013/562082>.
24. R. Gomathi, A. Ramu and A. Murugan, *Bioinorg. Chem. Appl.*, **2014**, 215392 (2014); <https://doi.org/10.1155/2014/215392>.
25. V.K. Chityala, K. Sathish Kumar, R. Macha, P. Tigulla and Shivaraj, *Bioinorg. Chem. Appl.*, **2014**, 691260 (2014); <https://doi.org/10.1155/2014/691260>.
26. Y. Peng, H. Zhong, Z.-F. Chen, Y.-C. Liu, G.-H. Zhang, Q.-P. Qin and H. Liang, *Chem. Pharm. Bull. (Tokyo)*, **62**, 221 (2014); <https://doi.org/10.1248/cpb.c13-00256>.
27. W. Hernández, J. Paz, F. Carrasco, A. Vaisberg, E. Spodine, J. Manzur, L. Hennig, J. Sieler, S. Blaurock and L. Beyer, *Bioinorg. Chem. Appl.*, **2013**, 524701 (2013); <https://doi.org/10.1155/2013/524701>.
28. K. Starčević, M. Kralj, K. Ester, I. Sabol, M. Grce, K. Pavelić and G. Karminski-Zamola, *Bioorg. Med. Chem.*, **15**, 4419 (2007); <https://doi.org/10.1016/j.bmc.2007.04.032>.
29. Z.C. Liu, B.D. Wang, Z.Y. Yang, Y. Li, D.D. Qin and T.R. Li, *Eur. J. Med. Chem.*, **44**, 4477 (2009); <https://doi.org/10.1016/j.ejmech.2009.06.009>.
30. M.A. Malik, O.A. Dar, P. Gull, M.Y. Wani and A.A. Hashmi, *Med. Chem. Commun.*, **9**, 409 (2018); <https://doi.org/10.1039/C7MD00526A>.
31. M.M. Abd-Elzاهر, A.A. Labib, H.A. Mousa, S.A. Moustafa, M.M. Ali and A.A. El-Rashedy, *Beni-Suef Univ. J. Basic Appl. Sci.*, **5**, 85 (2016); <https://doi.org/10.1016/j.bjbas.2016.01.001>.
32. R.M. Shafeeulla, G. Krishnamurthy, H.S. Bhojinaik, H.P. Shivarudrappa and Y. Shiralgi, *Beni-Suef Univ. J. Basic Appl. Sci.*, **6**, 332 (2017); <https://doi.org/10.1016/j.bjbas.2017.06.001>.
33. Y. Prashanthi, K. Kiranmai, Ira, K. Sathishkumar, V.K. Chityala and Shivaraj, *Bioinorg. Chem. Appl.*, **2012**, 948534 (2012); <https://doi.org/10.1155/2012/948534>.
34. Ö. Sahin, Ü.Ö. Özdemir, N. Seferoglu, Z.K. Genc, K. Kaya, B. Aydinler, S. Tekin and Z. Seferoglu, *J. Photochem. Photobiol.*, **178**, 428 (2018); <https://doi.org/10.1016/j.jphotobiol.2017.11.030>.
35. S. Jean, K. Cormier, A.E. Patterson, C.M. Vogels, G.A. Robichaud, A. Decken, S. Turcotte and S.A. Westcott, *Can. J. Chem.*, **93**, 1140 (2015); <https://doi.org/10.1139/cjc-2015-0157>.
36. R. Manikandan, P. Viswanathamurthi, K. Velmurugan, R. Nandhakumar, T. Hashimoto and A. Endo, *J. Photochem. Photobiol.*, **130**, 205 (2014); <https://doi.org/10.1016/j.jphotobiol.2013.11.008>.
37. S.A. Elsayed, B.J. Jean-Claude, I.S. Butler and S.I. Mostafa, *J. Mol. Struct.*, **1028**, 208 (2012); <https://doi.org/10.1016/j.molstruc.2012.05.073>.
38. F.A. El-Morsy, B.J. Jean-Claude, I.S. Butler, S.A. El-Sayed and S.I. Mostafa, *Inorg. Chim. Acta*, **423**, 144 (2014); <https://doi.org/10.1016/j.ica.2014.07.031>.
39. A.A. Alie El-Deen, A. El-Monem, E. El-Askalany, R. Halaoui, B.J. Jean-Claude, I.S. Butler and S.I. Mostafa, *J. Mol. Struct.*, **1036**, 161 (2013); <https://doi.org/10.1016/j.molstruc.2012.09.045>.
40. C.S. Allardyce and P.J. Dyson, *Dalton Trans.*, **45**, 3201 (2016); <https://doi.org/10.1039/C5DT03919C>.
41. S. Shen, H. Chen, T.F. Zhu, X.Q. Ma, J. Xu, W.J. Zhu, R.H. Chen, J. Xie, T.L. Ma, L. Jia, Y. Wang, and C.Y. Peng, *Oncol. Lett.*, **13**, 3169 (2017); <https://doi.org/10.3892/ol.2017.5857>.
42. W.-J. Lian, X.-T. Wang, C.-Z. Xie, H. Tian, X.-Q. Song, H.-T. Pan, X. Qiao and J.-Y. Xu, *Dalton Trans.*, **45**, 9073 (2016); <https://doi.org/10.1039/C6DT00461J>.
43. A. Paul, S. Anbu, G. Sharma, M.L. Kuznetsov, B. Koch, M.F.C. Guedes da Silva and A.J.L. Pombeiro, *Dalton Trans.*, **44**, 19983 (2015); <https://doi.org/10.1039/C5DT02880A>.
44. W.-J. Song, J.-P. Cheng, D.-H. Jiang, L. Guo, M.-F. Cai, H.-B. Yang and Q.-Y. Lin, *Spectrochim. Acta Part A: Mol. Biomol. Spectrosc.*, **121**, 70 (2014); <https://doi.org/10.1016/j.saa.2013.09.142>.
45. M. Gaber, H.A. El-Ghamry and S.K. Fathalla, *Spectrochim. Acta A Mol. Biomol. Spectrosc.*, **139**, 396 (2015); <https://doi.org/10.1016/j.saa.2014.12.057>.
46. Z. Li, H. Yan, G. Chang, M. Hong, J. Dou and M. Niu, *Photochem. Photobiol. B.*, **163**, 403 (2016); <https://doi.org/10.1016/j.jphotobiol.2016.09.005>.
47. X.Q. Zhou, Q. Sun, L. Jiang, S.T. Li, W. Gu, J.L. Tian, X. Liu and S.P. Yan, *Dalton Trans.*, **44**, 9516 (2015); <https://doi.org/10.1039/c5dt00931f>.
48. J. Jiao, M. Jiang, Y.T. Li, ZY. Wu and C.W. Yan, *J. Biochem. Mol. Toxicol.*, **28**, 47 (2014); <https://doi.org/10.1002/jbt.21535>.
49. P. Li, M. Niu, M. Hong, S. Cheng and J.J. Dou, *Inorg. Biochem.*, **137**, 101 (2014); <https://doi.org/10.1016/j.jinorgbio.2014.04.005>.
50. P. Jaividhya, M. Ganeshpandian, R. Dhivya, M.A. Akbarsha and M. Palaniandavar, *Dalton Trans.*, **44**, 11997 (2015); <https://doi.org/10.1039/c5dt00899a>.
51. C. Rajarajeswari, M. Ganeshpandian, M. Palaniandavar, A. Riyasdeen and M.A. Akbarsha, *J. Inorg. Biochem.*, **140**, 255 (2014); <https://doi.org/10.1016/j.jinorgbio.2014.07.016>.